Ixazomib (Ninlaro) gets FDA approval for Multiple Myeloma

Ixazomib (Ninlaro) gets FDA approval for Multiple Myeloma

The US Food and Drug Administration (FDA) announced yesterday that the agency has granted approval to ixazomib (Ninlaro) in combination with lenalidomide and dexamethasone for the treatment of patients having multiple myeloma, who have been treated with minimum one prior therapy.

Ixazomib is the first ever proteasome inhibitor to receive FDA approval. It has been given priority review and had got orphan drug designation.

Ixazomib has got the approval on the basis of efficacy results out of the TOURMALINE-MM1 trial. The trial contained 722 patients with myeloma who had already received prior treatment with between 1 and 3 other therapies. The participants were randomly assigned to lenalidomide and dexamethasone with (n = 360) or without (n = 362) ixazomib.

In February, the manufacturer declared results of an interim analysis and said that the trial had met its primary endpoint. The findings suggested that patients given ixazomib had notably improved progression-free survival in comparison to the ones with lenalidomide and dexamethasone alone.

The ones, who were assigned ixazomib more commonly, suffered diarrhea, thrombocytopenia, constipation, nausea, peripheral edema, peripheral neuropathy, vomiting, and back pain than patients on the lenalidomide/dexamethasone arm of the trial.

On the basis of the clinical trials’ results, the recommended starting dose of ixazomib is 4 mg orally on 1st, 8th, and 15th day of a 28-day cycle in combination with lenalidomide 25 mg every day on days 1 through 21 and dexamethasone 40 mg on days 1, 8, 15, and 22 of a treatment cycle of 28 days.

User login

You May Have Missed...

Study: There’s definitely a sweet spot when it comes to sexual frequency and hap
Fri, 11/20/2015 - 10:27

As per a study published on Wednesday in the journal of Psychological and Personality Science, there’s for sure a sweet spot if we talk about...

Nigeria Update

Fresh Polio Cases lead to WHO Travel Restrictions on Pakistan and Syria
Tue, 05/06/2014 - 00:45

World Health Organization has slapped international travel restrictions on Pakistan, Cameroon...

Economy Watch

US Import Prices decline in April
Thu, 05/14/2015 - 01:13

For a straight 10th month, US import prices declined in April. The decline could be due to the...

REM Google reports rise in Advertising Revenues

Health Tonight

Important Facts about diabetes
Important Facts about diabetes
Tue, 11/10/2015 - 03:30

Diabetes is among the leading reasons of disability and mortality in the United States. Efforts...

Simple lifestyle changes can help stay fit, study

Science Tonight

Challenges for those working on vulture conservation
Sun, 11/15/2015 - 05:46

Environmentalists have said that there are significant challenges in front of those working to...

UK News

Alzheimer's drug to help later stage patients
Wed, 10/28/2015 - 03:08

A new research has said that a common Alzheimer's drug can help later stage patients and help...


Sat, 01/17/2015 - 06:04

Aetna inc., health care company, on Friday announced that it has signed a deal with Gilead...

US News

Electric Eels curl their bodies to shock prey
5B-Electric Eels curl their bodies to shock prey
Tue, 11/03/2015 - 10:01

The electric eels are strong enough to hold and shock prey at 600V. This is 5 times vigorous...

US Department of Justice reaches settlement with more than 450 hospitals over cardiac device

Technology Tonight

Apple to make games a primary selling point of its new Apple TV Product
Mon, 09/07/2015 - 12:33

There is a lot of excitement about products to be launched at September 9’s event to be...